semaglutide cardiovascular outcomes news 2025 october Risks after GLP-1 Discontinuation Semaglutide cardiovascular outcomes align more

Dupixent (dupilumab) and Zepbound (tirzepatide) can be safely co-administered without known direct drug interactions, as they target completely different pat...

Semaglutide/Cyanocobalamin Semaglutide/Cyanocobalamin is an innovative new drug that is taking the weight loss market by storm

Amazon has launched a new GLP-1 weight loss program with same-day delivery.

There was also a small but statistically significant decrease in luteinising hormone and testosterone levels 120 min after exenatide dosing

PlexusDx explains the clinical rationale, safety considerations, and personalized treatment options available through compounded GLP-1 therapy